UBS Group
GTBP icon

UBS Group’s GT Biopharma GTBP Stock Holding History

UBS Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,839
Closed -$18.6K – 10383
2026
Q1 		$18.8K Buy
+1,839
New +$25.1K ﹤0.01% 7983
2025
Q4 		– Sell
-105
Closed -$1.86K – 10428
2025
Q3 		$1.54K Sell
105
-127
-55% -$4.74K ﹤0.01% 9322
2025
Q2 		$20.8K Buy
232
+130
+127% +$8.4K ﹤0.01% 8405
2025
Q1 		$5.5K Sell
102
-98
-49% -$5.76K ﹤0.01% 8984
2024
Q4 		$15.2K Buy
200
+44
+28% +$2.98K ﹤0.01% 8054
2024
Q3 		$9.01K Sell
156
-203
-57% -$12.1K ﹤0.01% 7806
2024
Q2 		$25.4K Buy
359
+318
+776% +$28.4K ﹤0.01% 7148
2024
Q1 		$4.53K Buy
41
+22
+116% +$2.91K ﹤0.01% 7614
2023
Q4 		$3.72K Buy
19
+7
+58% +$1.28K ﹤0.01% 7937
2023
Q3 		$2.11K Buy
12
+8
+200% +$1.65K ﹤0.01% 7767
2023
Q2 		$946 Sell
4
-6
-60% -$1.55K ﹤0.01% 8060
2023
Q1 		$4.29K Buy
10
+5
+100% +$2.86K ﹤0.01% 8208
2022
Q4 		$3.13K Buy
5
+1
+25% +$1.25K ﹤0.01% 9559
2022
Q3 		$5K Hold
4
– – ﹤0.01% 9195
2022
Q2 		$9K Sell
4
-2
-33% -$3.79K ﹤0.01% 8133
2022
Q1 		$13K Sell
6
-9
-60% -$19.8K ﹤0.01% 8048
2021
Q4 		$34K Buy
15
+9
+150% +$33.7K ﹤0.01% 7262
2021
Q3 		$32K Buy
6
+2
+50% +$15K ﹤0.01% 6692
2021
Q2 		$48K Sell
4
-1
-20% -$10.4K ﹤0.01% 6472
2021
Q1 		$27K Buy
+5
New +$21.8K ﹤0.01% 7094

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

UBS Group's GTBP Position: Q2 2026 in Review

UBS Group sold out of GT Biopharma (GTBP) in Q2 2026, closing a stake of 1,839 shares — an estimated $18.6K sold.

UBS Group first reported a position in GTBP in Q1 2021 and held it in 20 quarters. The position peaked at $48K in Q2 2021. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • UBS Group reported no remaining GT Biopharma position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 1,839 GT Biopharma shares in Q2 2026, an estimated $18.6K.
  • UBS Group first reported a position in GT Biopharma in Q1 2021 and held it in 20 quarters.
  • UBS Group's GT Biopharma position peaked at $48K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.